Subscribe to RSS
DOI: 10.1055/s-0042-1757744
On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
Funding This work was supported by the Thrombosis Research Institute (London, UK).
Abstract
Background Direct oral anticoagulants (DOACs) provide a safe, effective alternative to vitamin K antagonists (VKAs) for venous thromboembolism (VTE) treatment, as shown via intention-to-treat comparative effectiveness analysis. However, on-treatment analysis is imperative in observational studies because anticoagulation choice and duration are at investigators' discretion.
Objectives The aim of the study is to compare the effectiveness of DOACs and VKAs on 12-month outcomes in VTE patients using on-treatment analysis.
Methods The Global Anticoagulant Registry in the FIELD - VTE (GARFIELD-VTE) is a world-wide, prospective, non-interventional study observing treatment of VTE in routine clinical practice.
Results In total, 8,034 patients received VKAs (n = 3,043, 37.9%) or DOACs (n = 4,991, 62.1%). After adjustment for baseline characteristics and follow-up bleeding events, and accounting for possible time-varying confounding, all-cause mortality was significantly lower with DOACs than VKAs (hazard ratio: 0.58 [95% confidence interval 0.42–0.79]). Furthermore, patients receiving VKAs were more likely to die of VTE complications (4.9 vs. 2.2%) or bleeding (4.9 vs. 0.0%). There was no significant difference in rates of recurrent VTE (hazard ratio: 0.74 [0.55–1.01]), major bleeding (hazard ratio: 0.76 [0.47–1.24]), or overall bleeding (hazard ratio: 0.87 [0.72–1.05]) with DOACs or VKAs. Unadjusted analyses suggested that VKA patients with active cancer or renal insufficiency were more likely to die than patients treated with DOAC (52.51 [37.33–73.86] vs. 26.52 [19.37–36.29] and 9.97 [7.51–13.23] vs. 4.70 [3.25–6.81] per 100 person-years, respectively).
Conclusion DOACs and VKAs had similar rates of recurrent VTE and major bleeding. However, DOACs were associated with reduced all-cause mortality and a lower likelihood of death from VTE or bleeding compared with VKAs.
Keywords
venous thromboembolism - vitamin K antagonists - direct oral anticoagulants - on-treatment comparative effectiveness - anticoagulationPublication History
Received: 28 April 2022
Accepted: 29 August 2022
Article published online:
03 November 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Büller HR, Décousus H, Grosso MA. et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
- 2 Schulman S, Kearon C, Kakkar AK. et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
- 3 Bauersachs R, Berkowitz SD, Brenner B. et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
- 4 Agnelli G, Buller HR, Cohen A. et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
- 5 Kahn SR, Shapiro S, Wells PS. et al. SOX trial investigators. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383 (9920): 880-888
- 6 Weitz JI, Haas S, Ageno W. et al. Global anticoagulant registry in the field - venous thromboembolism (GARFIELD-VTE). Rationale and design. Thromb Haemost 2016; 116 (06) 1172-1179
- 7 Haas S, Ageno W, Weitz JI. et al. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. J Thromb Haemost 2019; 17 (10) 1694-1706
- 8 Bounameaux H, Haas S, Farjat AE. et al. Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thromb Res 2020; 191: 103-112
- 9 Schulz KF, Altman DG, Moher D. CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010; 7 (03) e1000251
- 10 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
- 11 Foundation NK. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2, suppl 1): S1-S266
- 12 Tripepi G, Chesnaye NC, Dekker FW, Zoccali C, Jager KJ. Intention to treat and per protocol analysis in clinical trials. Nephrology (Carlton) 2020; 25 (07) 513-517
- 13 van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw 2011; 45 (03) 1-67
- 14 Joffe M, Ten Have T, Feldman H, Kimmel S. Model selection, confounder control, and marginal structural models: review and new applications. Am Stat 2004; 58: 272-279
- 15 Olié V, Fuhrman C, Chin F, Lamarche-Vadel A, Scarabin PY, de Peretti C. Time trends in pulmonary embolism mortality in France, 2000-2010. Thromb Res 2015; 135 (02) 334-338
- 16 Mai V, Guay CA, Perreault L. et al. Extended anticoagulation for VTE: a systematic review and meta-analysis. Chest 2019; 155 (06) 1199-1216
- 17 Haas S, Mantovani LG, Kreutz R. et al. Anticoagulant treatment for venous thromboembolism: a pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies. Res Pract Thromb Haemost 2021; 5 (03) 426-438
- 18 Wu O, Morris S, Larsen TB. et al. Effectiveness and safety of nonvitamin K oral anticoagulants rivaroxaban and apixaban in patients with venous thromboembolism: a meta-analysis of real-world studies. Cardiovasc Ther 2022; 2022: 2756682
- 19 Poli D, Antonucci E, Bertù L. et al. coordinator of START2 Register. Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: results from the prospective multicenter START2-Register Study. Thromb Res 2019; 183: 28-32
- 20 Weitkunat R, Baker G, Lüdicke F. Intention-to-treat analysis but for treatment intention: how should consumer product randomized controlled trials be analyzed?. Int J Stat Med Res 2016; 5: 90-98
- 21 Ellenberg JH. Intent-to-treat analysis versus as-treated analysis. Drug Inf J 1996; 30 (02) 535-544
- 22 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
- 23 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
- 24 Agnelli G, Becattini C, Meyer G. et al. Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
- 25 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
- 26 Wakakura S, Hara F, Fujino T. et al. Comparison of direct oral anticoagulants and warfarin in the treatment of deep venous thrombosis in the chronic phase. Int Heart J 2018; 59 (01) 126-135